Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Clinical Knowledge Summaries (CKS)
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Life sciences
More from NICE
Home
NICE guidance
In consultation
In consultation: Guidance and quality standards
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic prioritisation
Filter (7 applied)
Skip to results
Keyword or reference number
Keyword or reference number
Apply filter
Consultation end date
Consultation end date
From date
To date
Apply date filters
Type
(
1 selected
)
Type
Guidance (12)
Guidance programme
(
6 selected
)
Guidance programme
Antimicrobial prescribing guidelines (0)
Cancer service guidelines (0)
Diagnostics guidance (1)
Highly specialised technologies guidance (1)
Interventional procedures guidance (2)
Medicines practice guidelines (0)
Public health guidelines (0)
Technology appraisal guidance (11)
Apply filters
Showing 1 to 10 of 12
Sort by
Date
Title
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance programme: Diagnostics guidance
Remove Guidance programme: Diagnostics guidance filter
Guidance programme: Antimicrobial prescribing guidelines
Remove Guidance programme: Antimicrobial prescribing guidelines filter
Guidance programme: Cancer service guidelines
Remove Guidance programme: Cancer service guidelines filter
Guidance programme: Medicines practice guidelines
Remove Guidance programme: Medicines practice guidelines filter
Guidance programme: Public health guidelines
Remove Guidance programme: Public health guidelines filter
Guidance and quality standards in consultation
Title
Consultation
Type
Consultation end date
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]
Draft guidance
Technology appraisal guidance
17 December 2025
Tarlatamab for treating small-cell lung cancer that has progressed after platinum-based chemotherapy ID6617
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
Technology appraisal guidance
17 December 2025
Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma
Review proposal consultation
Technology appraisal guidance
16 December 2025
Guidance on the use of electroconvulsive therapy
Review proposal consultation
Technology appraisal guidance
16 December 2025
Pharmalgen for the treatment of bee and wasp venom allergy
Review proposal consultation
Technology appraisal guidance
16 December 2025
Pharmalgen for the treatment of bee and wasp venom allergy
Review proposal consultation
Technology appraisal guidance
16 December 2025
Artificial intelligence software to help detect and characterise colorectal polyps
Diagnostics consultation
Diagnostics guidance
11 December 2025
Toripalimab with chemotherapy for untreated recurrent or metastatic nasopharyngeal cancer ID6406
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
Technology appraisal guidance
11 December 2025
Dostarlimab with platinum-based chemotherapy for advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency [ID6415]
Final draft guidance
Technology appraisal guidance
9 December 2025
Giredestrant with everolimus for treating oestrogen-receptor positive HER2-negative advanced breast cancer after cyclin-dependent kinase 4 and 6 inhibitor and endocrine treatment ID6576
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
Technology appraisal guidance
8 December 2025
Current page
1
2
Page
1
of
2
Next page
Results per page
10
25
50
All
Back to top